{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:46:20Z","timestamp":1783745180446,"version":"3.55.0"},"reference-count":109,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008871","name":"Juvenile Diabetes Research Foundation United States of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Type 1 diabetes (T1D) is a T-cell mediated autoimmune disease. Short-term treatment with agents targeting T cells, B cells and inflammatory cytokines to modify the disease course resulted in a short-term pause in disease activity. Lessons learnt from these trials will be discussed in this review. It is expected that effective disease-modifying agents will become available for use in earlier stages of T1D. Progress has been made to analyze antigen-specific T cells with standardization of T cell assay and discovery of antigen epitopes but there are many challenges. High-dimensional profiling of gene, protein and TCR expression at single cell level with innovative computational tools should lead to novel biomarker discovery. With this, assays to detect, quantify and characterize the phenotype and function of antigen-specific T cells will continuously evolve. An improved understanding of T cell responses will help researchers and clinicians to better predict disease onset, and progression, and the therapeutic efficacy of interventions to prevent or arrest T1D.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1206874","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T16:30:01Z","timestamp":1686069001000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Monitoring immunomodulation strategies in type 1 diabetes"],"prefix":"10.3389","volume":"14","author":[{"given":"Balasubramanian","family":"Krishnamurthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lacorcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W. H.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen E.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart I.","family":"Mannering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/cei.12699","article-title":"The case for an autoimmune aetiology of type 1 diabetes","volume":"183","author":"Mannering","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/dia.2018.0384","article-title":"State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018","volume":"21","author":"Foster","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1172\/JCI109704","article-title":"Linkage analysis between the major histocompatibility system and insulin-dependent diabetes in families with patients in two consecutive generations","volume":"65","author":"Barbosa","year":"1980","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/db07-1331","article-title":"HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families","volume":"57","author":"Erlich","year":"2008","journal-title":"Diabetes"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.6285","article-title":"Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children","volume":"309","author":"Ziegler","year":"2013","journal-title":"Jama"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the endocrine society, and the American diabetes association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI94549","article-title":"Autoreactive T cells in type 1 diabetes","volume":"127","author":"Pugliese","year":"2017","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4203","article-title":"Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes","volume":"22","author":"Babon","year":"2016","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jim.2005.01.001","article-title":"An efficient method for cloning human autoantigen-specific T cells","volume":"298","author":"Mannering","year":"2005","journal-title":"J Immunol Methods"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0858","article-title":"Proinsulin-specific, HLA-DQ8, and HLA-DQ8-transdimer-restricted CD4+ T cells infiltrate islets in type 1 diabetes","volume":"64","author":"Pathiraja","year":"2015","journal-title":"Diabetes"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1809208115","article-title":"Proinsulin c-peptide is an autoantigen in people with type 1 diabetes","volume":"115","author":"So","year":"2018","journal-title":"Proc Natl Acad Sci U States America"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature03625","article-title":"Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope","volume":"435","author":"Kent","year":"2005","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad2791","article-title":"Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion","volume":"351","author":"Delong","year":"2016","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1084\/jem.20111187","article-title":"Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients","volume":"209","author":"Coppieters","year":"2012","journal-title":"J Exp Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35449","article-title":"CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope","volume":"118","author":"Skowera","year":"2008","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2206","article-title":"Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes","volume":"13","author":"Bulek","year":"2012","journal-title":"Nat Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/db20-0908","article-title":"One in ten CD8(+) cells in the pancreas of living individuals with recent-onset type 1 diabetes recognizes the preproinsulin epitope PPI(15-24)","volume":"70","author":"Rodriguez-Calvo","year":"2021","journal-title":"Diabetes"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/db07-1594","article-title":"The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment","volume":"57","author":"Martinuzzi","year":"2008","journal-title":"Diabetes"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI19585","article-title":"Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health","volume":"113","author":"Arif","year":"2004","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/db09-1486","article-title":"Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers","volume":"59","author":"Velthuis","year":"2010","journal-title":"Diabetes"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2005.09.018","article-title":"GAD65- and proinsulin-specific CD4+ T-cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects","volume":"25","author":"Oling","year":"2005","journal-title":"J Autoimmun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.5.2781","article-title":"Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects","volume":"176","author":"Yang","year":"2006","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051251","article-title":"The insulin a-chain epitope recognized by human T cells is posttranslationally modified","volume":"202","author":"Mannering","year":"2005","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0332","article-title":"Beta-cell-specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure","volume":"64","author":"Skowera","year":"2014","journal-title":"Diabetes"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.9.5785","article-title":"Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes","volume":"179","author":"Monti","year":"2007","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0305","article-title":"Comparing beta cell preservation across clinical trials in recent-onset type 1 diabetes","volume":"22","author":"Jacobsen","year":"2020","journal-title":"Diabetes Technol Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh1654","article-title":"Immunotherapy: building a bridge to a cure for type 1 diabetes","volume":"373","author":"Bluestone","year":"2021","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030215","article-title":"Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase","volume":"197","author":"Jaeckel","year":"2003","journal-title":"J Exp Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/ni1120","article-title":"Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes","volume":"5","author":"Jaeckel","year":"2004","journal-title":"Nat Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29602","article-title":"Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP","volume":"116","author":"Krishnamurthy","year":"2006","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1101\/2023.02.12.528226","article-title":"Extra-islet expression of islet antigen boosts T-cell exhaustion to prevent autoimmune diabetes","author":"Selck","year":"2023","journal-title":"bioRxiv"},{"key":"B32","doi-asserted-by":"publisher","first-page":"191ra82","DOI":"10.1126\/scitranslmed.3006103","article-title":"Plasmid-encoded proinsulin preserves c-peptide while specifically reducing proinsulin-specific CD8(+) T cells in type 1 diabetes","volume":"5","author":"Roep","year":"2013","journal-title":"Sci Transl Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05376-1","article-title":"Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial","volume":"64","author":"Assfalg","year":"2021","journal-title":"Diabetologia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.17070","article-title":"Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial","volume":"318","author":"Krischer","year":"2017","journal-title":"Jama"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf7779","article-title":"Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes","volume":"9","author":"Alhadj Ali","year":"2017","journal-title":"Sci Transl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.2928","article-title":"Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the pre-POINT randomized clinical trial","volume":"313","author":"Bonifacio","year":"2015","journal-title":"JAMA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0523","article-title":"Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial","volume":"34","author":"Vehik","year":"2011","journal-title":"Diabetes Care"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2337\/db10-1360","article-title":"Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes","volume":"60","author":"Fourlanos","year":"2011","journal-title":"Diabetes"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107096","article-title":"GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus","volume":"366","author":"Ludvigsson","year":"2012","journal-title":"New Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60895-7","article-title":"Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial","volume":"378","author":"Wherrett","year":"2011","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-022-01852-9","article-title":"Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE extension trial)","volume":"59","author":"Casas","year":"2022","journal-title":"Acta Diabetol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"9391845","DOI":"10.1155\/2018\/9391845","article-title":"Intralymphatic glutamic acid decarboxylase-alum administration induced Th2-Like-Specific immunomodulation in responder patients: a pilot clinical trial in type 1 diabetes","volume":"2018","author":"Tavira","year":"2018","journal-title":"J Diabetes Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12611","article-title":"Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: a randomized clinical trial","volume":"19","author":"Elding Larsson","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804328","article-title":"GAD treatment and insulin secretion in recent-onset type 1 diabetes","volume":"359","author":"Ludvigsson","year":"2008","journal-title":"New Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.10.2348","article-title":"Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes","volume":"27","author":"Harrison","year":"2004","journal-title":"Diabetes Care"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2251","article-title":"Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial","volume":"36","author":"Axelsson","year":"2013","journal-title":"Diabetes Care"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.10.005","article-title":"Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin b-chain immunotherapy","volume":"34","author":"Orban","year":"2010","journal-title":"J Autoimmun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5448.2010.00674.x","article-title":"Parenteral insulin suppresses T cell proliferation to islet antigens","volume":"12","author":"Greenbaum","year":"2011","journal-title":"Pediatr Diabetes"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2008.03814.x","article-title":"Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study","volume":"155","author":"Thrower","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e29008","DOI":"10.1371\/journal.pone.0029008","article-title":"Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes","volume":"6","author":"Axelsson","year":"2011","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2010.10.004","article-title":"GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients","volume":"138","author":"Hjorth","year":"2011","journal-title":"Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2337\/db19-0119","article-title":"Standardizing T-cell biomarkers in type 1 diabetes: challenges and recent advances","volume":"68","author":"Ahmed","year":"2019","journal-title":"Diabetes"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nature03523","article-title":"Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice","volume":"435","author":"Nakayama","year":"2005","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2337\/diab.46.1.34","article-title":"Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice","volume":"46","author":"French","year":"1997","journal-title":"Diabetes"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-978750","article-title":"Glutamate decarboxylase and GABA in pancreatic islets: lessons from knock-out mice","volume":"31","author":"Kash","year":"1999","journal-title":"Horm Metab Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1252-z","article-title":"IA-2 is not required for the development of diabetes in NOD mice","volume":"47","author":"Kubosaki","year":"2004","journal-title":"Diabetologia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2337\/db11-0220","article-title":"Deletion of the G6pc2 gene encoding the islet-specific glucose-6-phosphatase catalytic subunit-related protein does not affect the progression or incidence of type 1 diabetes in NOD\/ShiLtJ mice","volume":"60","author":"Oeser","year":"2011","journal-title":"Diabetes"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0913835107","article-title":"In situ recognition of autoantigen as an essential gatekeeper in autoimmune CD8+ T cell inflammation","volume":"107","author":"Wang","year":"2010","journal-title":"Proc Natl Acad Sci U States America"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e86065","DOI":"10.1172\/jci.insight.86065","article-title":"Perinatal tolerance to proinsulin is sufficient to prevent autoimmune diabetes","volume":"1","author":"Jhala","year":"2016","journal-title":"JCI Insight"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.03.015","article-title":"Reversal of autoimmunity by boosting memory-like autoregulatory T cells","volume":"32","author":"Tsai","year":"2010","journal-title":"Immunity"},{"key":"B61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/imcb.12506","article-title":"Tolerance induction by liposomes targeting a single CD8 epitope IGRP(206-214) in a model of type 1 diabetes is impeded by co-targeting a CD4(+) islet epitope","volume":"100","author":"Buckle","year":"2022","journal-title":"Immunol Cell Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00418","article-title":"Beyond CTLA-4 and PD-1, the generation z of negative checkpoint regulators","volume":"6","author":"Le Mercier","year":"2015","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01379-9","article-title":"Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity","volume":"24","author":"Vignali","year":"2022","journal-title":"Nat Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01103","article-title":"Intestinal delivery of proinsulin and IL-10 via lactococcus lactis combined with low-dose anti-CD3 restores tolerance outside the window of acute type 1 diabetes diagnosis","volume":"11","author":"Cook","year":"2020","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061462","article-title":"Resolution of a chronic viral infection after interleukin-10 receptor blockade","volume":"203","author":"Ejrnaes","year":"2006","journal-title":"J Exp Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0811139106","article-title":"IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection","volume":"105","author":"Brooks","year":"2008","journal-title":"Proc Natl Acad Sci U States America"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J Exp Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13762","article-title":"Diabetes associated with immune checkpoint inhibition: presentation and management challenges","volume":"35","author":"Galligan","year":"2018","journal-title":"Diabetes Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01210-5","article-title":"Autoreactive CD8(+) T cells are restrained by an exhaustion-like program that is maintained by LAG3","volume":"23","author":"Grebinoski","year":"2022","journal-title":"Nat Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.4049\/jimmunol.2100362","article-title":"Self-renewing islet TCF1(+) CD8 T cells undergo IL-27-Controlled differentiation to become TCF1(-) terminal effectors during the progression of type 1 diabetes","volume":"207","author":"Ciecko","year":"2021","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192362","article-title":"Single-cell RNA sequencing of murine islets shows high cellular complexity at all stages of autoimmune diabetes","volume":"217","author":"Zakharov","year":"2020","journal-title":"J Exp Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/nature14468","article-title":"T-Cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142680","article-title":"Exhausted-like CD8+ T cell phenotypes linked to c-peptide preservation in alefacept-treated T1D subjects","volume":"6","author":"Diggins","year":"2021","journal-title":"JCI Insight"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126595","article-title":"Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression","volume":"130","author":"Wiedeman","year":"2020","journal-title":"J Clin Invest"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0626","article-title":"B-lymphocyte depletion with rituximab and beta-cell function: two-year results","volume":"37","author":"Pescovitz","year":"2014","journal-title":"Diabetes Care"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, b-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"New Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0604","article-title":"Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment","volume":"37","author":"Orban","year":"2014","journal-title":"Diabetes Care"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60886-6","article-title":"Co-Stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"378","author":"Orban","year":"2011","journal-title":"Lancet"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78492","article-title":"Anti-thymocyte globulin\/G-CSF treatment preserves beta cell function in patients with established type 1 diabetes","volume":"125","author":"Haller","year":"2015","journal-title":"J Clin Invest"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"New Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05317-y","article-title":"A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes","volume":"64","author":"Keymeulen","year":"2021","journal-title":"Diabetologia"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043980","article-title":"Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes","volume":"352","author":"Keymeulen","year":"2005","journal-title":"New Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"New Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70111-6","article-title":"Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial","volume":"1","author":"Rigby","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1172\/JCI81722","article-title":"Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients","volume":"125","author":"Rigby","year":"2015","journal-title":"J Clin Invest"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2006136","article-title":"Golimumab and beta-cell function in youth with new-onset type 1 diabetes","volume":"383","author":"Quattrin","year":"2020","journal-title":"New Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0054","article-title":"Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study","volume":"32","author":"Mastrandrea","year":"2009","journal-title":"Diabetes Care"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00019-X","article-title":"Anti-interleukin-21 antibody and liraglutide for the preservation of beta-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"von Herrath","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150074","article-title":"IL-6 receptor blockade does not slow beta cell loss in new-onset type 1 diabetes","volume":"6","author":"Greenbaum","year":"2021","journal-title":"JCI Insight"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60023-9","article-title":"Nterleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials","volume":"381","author":"Moran","year":"2013","journal-title":"Lancet"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3917-4","article-title":"Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial","volume":"59","author":"Gitelman","year":"2016","journal-title":"Diabetologia"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0236","article-title":"Teplizumab preserves c-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled protege trial","volume":"62","author":"Hagopian","year":"2013","journal-title":"Diabetes"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0345","article-title":"Teplizumab (anti-CD3 mAb) treatment preserves c-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders","volume":"62","author":"Herold","year":"2013","journal-title":"Diabetes"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4786-9","article-title":"Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis","volume":"62","author":"Perdigoto","year":"2019","journal-title":"Diabetologia"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0049","article-title":"Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments tregs yet transiently impairs beta-cell function","volume":"61","author":"Long","year":"2012","journal-title":"Diabetes"},{"key":"B98","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.clim.2015.05.023","article-title":"Biomarkers for antigen immunotherapy in allergy and type 1 diabetes","volume":"161","author":"Odegard","year":"2015","journal-title":"Clin Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202049067","article-title":"Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes","volume":"52","author":"Yang","year":"2022","journal-title":"Eur J Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2003.09.004","article-title":"A sensitive method for detecting proliferation of rare autoantigen-specific human T cells","volume":"283","author":"Mannering","year":"2003","journal-title":"J Immunol Methods"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1172\/JCI120555","article-title":"Autoreactive T effector memory differentiation mirrors beta cell function in type 1 diabetes","volume":"128","author":"Yeo","year":"2018","journal-title":"J Clin Invest"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.04087.x","article-title":"Islet inflammation and CXCL10 in recent-onset type 1 diabetes","volume":"159","author":"Roep","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K10E-076","article-title":"Expression of chemokines, CXC chemokine ligand 10 (CXCL10) and CXCR3 in the inflamed islets of patients with recent-onset autoimmune type 1 diabetes","volume":"57","author":"Uno","year":"2010","journal-title":"Endocr J"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0091","article-title":"Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes","volume":"58","author":"Tanaka","year":"2009","journal-title":"Diabetes"},{"key":"B105","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.cmet.2018.11.014","article-title":"A map of human type 1 diabetes progression by imaging mass cytometry","volume":"29","author":"Damond","year":"2019","journal-title":"Cell Metab"},{"key":"B106","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.cmet.2019.01.003","article-title":"Multiplexed In situ imaging mass cytometry analysis of the human endocrine pancreas and immune system in type 1 diabetes","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Metab"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01073-2","article-title":"High-throughput and high-dimensional single-cell analysis of antigen-specific CD8(+) T cells","volume":"22","author":"Ma","year":"2021","journal-title":"Nat Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4380","article-title":"Simultaneous epitope and transcriptome measurement in single cells","volume":"14","author":"Stoeckius","year":"2017","journal-title":"Nat Methods"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg5669","article-title":"CD8(+) T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients","volume":"6","author":"Mallajosyula","year":"2021","journal-title":"Sci Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1206874\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T16:30:05Z","timestamp":1686069005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1206874\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":109,"alternative-id":["10.3389\/fimmu.2023.1206874"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1206874","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"article-number":"1206874"}}